DNRS 6630 Week 9 Special Populations Paper Example

Special Populations Paper: What Pregnancy, Later Life, and Impaired Elimination Change About Written Reasoning for Psychotropics

Student Name

College of Nursing, Walden University

DNRS 6630: Psychopharmacologic Approaches to Treatment of Psychopathology

Instructor Name

Month Day, Year

Special Populations Paper: What Pregnancy, Later Life, and Impaired Elimination Change About Written Reasoning for Psychotropics

Each of the three sections below follows the same pattern: the physiologic change, described as a change in how the body handles a compound; what that change means for the reasoning a clinical document can offer; the evidence situation; and where the conversation about uncertainty is recorded. No recommendation is made for any population.

Pregnancy

The change. Pregnancy alters nearly every step of how the body handles a drug. Plasma volume and body water expand, albumin concentration falls, kidney blood flow and filtration rise, and the activity of several liver enzymes changes, some increasing and others decreasing. A systematic review of pregnancy-associated pharmacokinetic studies found that, for many drugs studied, clearance increased and concentrations fell, most often in the third trimester, though the direction differed by drug and enzyme pathway (Pariente et al., 2016).

What it means for written reasoning. A document cannot borrow the general-population expectation that a stable dose gives a stable level. It has to say that concentrations may change across trimesters and again after delivery, when physiology returns toward baseline within weeks. It also has to hold two risks together: the risk of the drug to the fetus and the risk of untreated illness to the mother and the pregnancy, since stopping treatment is itself a choice with consequences.

The period after delivery deserves its own line in any document. As plasma volume, kidney filtration, and enzyme activity return toward their prepregnancy state over the following weeks, a dose that was raised to keep pace with pregnancy may produce higher exposure than intended. Breastfeeding adds a second person whose exposure depends on how much drug passes into milk and on the infant's own immature clearance. Neither question is answered by the evidence on pregnancy itself, and a document that treats delivery as the end of the special situation has stopped reasoning too early.

The evidence situation. Randomized trials in pregnancy are rare, so most evidence on fetal risk comes from registries and observational cohorts. In a large population-based cohort, an association between first-trimester antidepressant use and cardiac defects shrank toward no effect as the analysis accounted for confounding, including the depression itself (Huybrechts et al., 2014). That is reassuring for that outcome but shows how much the answer depends on adjustment, and it says little about outcomes the study did not examine.

Where the conversation is recorded. The document should record what the patient was told about the evidence on both sides, including what is unknown, and what she chose, in her words.

Later Life

The change. With age, body fat increases while body water and lean mass fall, kidney function declines gradually, liver blood flow falls, and sensitivity at some drug targets, especially in the central nervous system, increases (Mangoni & Jackson, 2004).

What it means for written reasoning. A document cannot assume that a standard dose produces a standard exposure or a standard effect. Lipid-soluble psychotropics accumulate and linger, and sedative and anticholinergic effects appear at concentrations a younger adult would tolerate. The reasoning must also account for harms that are more consequential at this age, falls, confusion, and low sodium, which the Beers Criteria identify for several psychotropic classes (American Geriatrics Society Beers Criteria Update Expert Panel, 2023).

The evidence situation. Older adults, particularly those with several conditions and many medicines, are underrepresented in trials. Much of what is known about harms comes from observational studies and consensus criteria rather than from randomized comparisons in the people most affected.

Where the conversation is recorded. The document should record the person's own priorities, for example independence or avoiding falls, and how the uncertainty was weighed against them.

Impaired Elimination

The change. When kidney or liver function falls, drugs and active metabolites cleared by that organ accumulate. For drugs cleared by the kidney, exposure rises roughly in step with the fall in clearance; for those cleared by the liver, the effect depends on the drug's extraction and the pathway involved.

What it means for written reasoning. A document must state which organ clears the drug and its metabolites, the patient's measured function, and the interval at which that function will be rechecked, because a dose that was right at the start can become wrong as function changes without any change in the prescription.

The evidence situation. For antidepressants in advanced chronic kidney disease, a systematic review found that pharmacokinetic data were limited for many drugs and that evidence of efficacy and safety in this population was scarce, with few small trials (Nagler et al., 2012). Much of what is written about dosing in impaired elimination is extrapolated from single-dose studies rather than tested in people treated over time. That is the widespread practice resting on the thinnest support: confident dosing statements built on pharmacokinetic inference rather than outcome data.

Where the conversation is recorded. The document should record that the patient was told the evidence is limited, what will be monitored because of that, and who will recheck organ function. If the patient's function is expected to change, for example during a planned surgery or a course of a nephrotoxic drug, the document should name that event as a reason to review.

Across the Three

Set side by side, the three populations share a pattern that general-population writing tends to hide. In each, the relationship between dose and exposure is less predictable than usual, the people concerned are the ones least studied in trials, and the harms that matter most are not the ones trials are designed to measure. The differences are just as instructive. In pregnancy, the physiology changes quickly and then reverses; in later life, it changes slowly and in one direction; in impaired elimination, it can change abruptly with an illness. A document written for any of them therefore needs a date on its reasoning: a point at which the assumptions it rests on will be checked again. That requirement, more than any particular drug choice, is what separates careful writing for these populations from borrowed confidence.

References

American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081. https://doi.org/10.1111/jgs.18372

Huybrechts, K. F., Palmsten, K., Avorn, J., Cohen, L. S., Holmes, L. B., Franklin, J. M., Mogun, H., Levin, R., Kowal, M., Setoguchi, S., & Hernández-Díaz, S. (2014). Antidepressant use in pregnancy and the risk of cardiac defects. The New England Journal of Medicine, 370(25), 2397-2407. https://doi.org/10.1056/NEJMoa1312828

Mangoni, A. A., & Jackson, S. H. D. (2004). Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. British Journal of Clinical Pharmacology, 57(1), 6-14. https://doi.org/10.1046/j.1365-2125.2003.02007.x

Nagler, E. V., Webster, A. C., Vanholder, R., & Zoccali, C. (2012). Antidepressants for depression in stage 3-5 chronic kidney disease: A systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation, 27(10), 3736-3745. https://doi.org/10.1093/ndt/gfs295

Pariente, G., Leibson, T., Carls, A., Adams-Webber, T., Ito, S., & Koren, G. (2016). Pregnancy-associated changes in pharmacokinetics: A systematic review. PLOS Medicine, 13(11), Article e1002160. https://doi.org/10.1371/journal.pmed.1002160